Immuron Limited
IMRN · Price history
Price at last available close
$0.93
−$0.23 (-19.81%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Immuron Limited
Primary reporting period: 2026-06-30 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products.
How they make money
Immuron Limited is a biopharmaceutical company that generates revenue primarily through the commercial sale of its proprietary hyperimmune bovine colostrum-based products. The company focuses on developing and marketing oral immunotherapeutic products that target infectious diseases and gastrointestinal disorders, while also investing in research and development for new drug candidates.
Products & services
The company's primary commercial products are Travelan and Protectyn, which are over-the-counter dietary supplements designed to support digestive health and provide protection against certain gastrointestinal pathogens.
Brands & revenue mix
A dietary supplement for the prevention of traveler's diarrhea.
Separate brand revenue is not available in this research.Source
A dietary supplement for digestive health support.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Retail consumers of dietary supplementsSource
Customer concentration
The company does not disclose specific major customers or significant concentration in its 2026 annual report.
Suppliers, materials & equipment
- Bovine colostrum suppliers — The company relies on third-party suppliers for the collection and processing of bovine colostrum, which is the primary raw material for its products.Source
Business relationships & partnerships
- Monash University — A research collaboration focused on developing new therapeutic drug candidates targeting antimicrobial resistant pathogens.Source
Strengths
- Proprietary hyperimmune bovine colostrum technology platformSource
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Opportunity Score is currently unavailable; Wall Street Score remains independently validated.
The unavailable Opportunity Score is a separate model output. It must not be substituted with zero or inferred from the company score.
Diluted weighted-average shares increased 42.4% year over year.
Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
35
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
55
Fair
Financial Strength
67
Business Quality / Moat
40
Management
40
Growth Quality
100
Risk / Durability
17
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Model Outlook
12-month model · What does the model think happens next?
Outperformance analysis is not currently available.
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
A current Opportunity Score is not available.
The 12-month model outlook is not currently available.
- •Balance-sheet / debt profile scores strongly
- •Asset quality scores strongly
- •Debt service risk
- •Valuation is a weaker part of the current profile
Company-specific research
Questions worth answering for IMRN
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can IMRN maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can IMRN fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is IMRN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for IMRN to reach sustainable profitability?
- •What future growth or profitability would be needed to justify IMRN's current valuation?
Essential Investment Snapshot
Wall Street Score
35
Market Cap
$6.0M
P/E Ratio
-1.4
EPS
$-0.84
52-Week High
$2.39
52-Week Low
$0.68
Beta
0.51
Shares Outstanding
7.4M
Total Revenue
$8.8M
Total Debt
$0
Dividend
No current dividend
Liquidation Value / Share
$1.03
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for IMRN
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-321.9x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on IMRN.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary hyperimmune bovine colostrum technology platform.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on clinical trial success and regulatory approval for new drug candidates.
- −Reliance on third-party manufacturers and suppliers.
- −Diluted weighted-average shares increased 42.4% year over year.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
33
Aug 14, 2026
Change
+2.3
points
Current Score
35
Oct 1, 2026
Category Changes
IMRN increased 2.3 points because Debt improved by 8.8 points, Asset improved by 19.9 points, Buffett improved by 3.2 points.
Positive Contributors
- + Debt improved by 8.8 points
- + Asset improved by 19.9 points
- + Buffett improved by 3.2 points
Negative Contributors
- − Moat declined by 11.2 points
Projected Score
Projected Score
31
Projected Change
-4.0 points
Preliminary comparable-period financial changes suggest decline of approximately 4.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$0.93
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.8M | $5.2M | $5.1M | $3.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $3.1M | $1.9M | $1.8M | $1.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $5.6M | $3.4M | $3.3M | $2.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $2.5M | $0.00 | $2.5M | $3.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $9.7M | $5.3M | $5.5M | $4.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $11.9M | $6.6M | $7.0M | $6.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$6.3M | -$3.2M | -$3.7M | -$3.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$6.2M | -$3.2M | -$3.7M | -$4.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $10K | $10K | $5K | $5K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$6.0M | -$3.0M | -$3.6M | -$4.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$430K | -$424K | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$5.5M | -$2.6M | -$3.6M | -$4.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.84 | $-0.35 | $-0.63 | $-0.85 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 8.13M | 7.44M | 5.77M | 5.70M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 8.13M | 7.44M | 5.77M | 5.70M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$2.5M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.17
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-100.0%
Cash Change
+218.6%
Margin Change
+29.6 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included revenue growth, cash levels, debt levels, net income margin. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 8.7%. EPS declined 48.9%. Cash increased 218.6%. Total debt declined 100.0%. Net income margin improved by 29.6 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyRumor Mill · IMRN
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial